ASH 2024 Summary: MPN Highlights and Clinical Implications

2024 ASH Annual Meeting Insights Hub

D. Tremblay

ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why, and How

2024 ASH Annual Meeting Insights Hub

J. Kiladjian

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

Allele Burden in MPN: Practical Considerations

16th International Congress on Myeloproliferative Neoplasms

R. Rampal

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

Novel Agents for MPNs in 2024

16th International Congress on Myeloproliferative Neoplasms

N. Pemmaraju

ASH 2024 Insights: Final Analysis of Pegylated Interferon in PV and …

2024 ASH Annual Meeting Insights Hub

L. Masarova

A Decade of Ruxolitinib in Polycythemia Vera: Clinical Efficacy and …

Lucia Masarova

Experts Discuss Pros and Cons of Treatment Approaches in PV

HemeHub

T. Bat, A. Tefferi

Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…

BMFcases

T. Bat, A. Tefferi

PV and Its Relationship to Acute Leukemia

16th International Congress on Myeloproliferative Neoplasms

J. Spivak

2024 Updates in PV/ET

University of Colorado Division of Hematology

B. McMahon

Experts Address Clinical Questions in PV: Utility of Aspirin, Rusfer…

HemeHub

T. Bat, A. Tefferi

Current Treatment of Polycythemia Vera

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Eşkazan